Assessing McKesson (MCK) Valuation After Q3 Earnings Beat And Upgraded Earnings Outlook

Why McKesson’s latest earnings report matters for shareholders

McKesson (MCK) shares were in focus after fiscal Q3 2026 results came in ahead of analyst expectations, with management lifting its full-year non-GAAP earnings growth outlook to a range of 17 to 19%, pointing to momentum across oncology and biopharma services.

See our latest analysis for McKesson.

At a share price of US$987.37, McKesson has seen strong recent momentum, with a 30 day share price return of 18.79% and a 1 year total shareholder return of 53.67%. This builds on an approximately 7x total shareholder return over five years as the market reacts to the latest earnings beat and upgraded outlook.

If this earnings update has you thinking about where else growth and healthcare trends might show up, it could be a good moment to scan 28 healthcare AI stocks for other ideas riding similar themes.

With McKesson trading near US$1,000 and already very close to analyst price targets, the key question is whether that reported intrinsic discount still signals value, or if the latest results mean future growth is already fully priced in.

Most Popular Narrative: 1% Overvalued

McKesson’s most followed narrative pegs fair value at $980.40, a touch below the last close of $987.37, which puts the current premium under the microscope.

Increasing complexity of the pharmaceutical supply chain (e.g. biosimilars, cold chain logistics, personalized medicine) disproportionately benefits large, sophisticated distributors like McKesson, enabling competitive market share gains and enhanced supply chain resiliency, contributing to both top-line and margin expansion.

Read the complete narrative.

Want to see what is baked into that near fair value call? The narrative leans heavily on steadier revenue growth, firmer margins, and a future earnings multiple that assumes McKesson keeps earning its premium status.

Result: Fair Value of $980.40 (OVERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, those assumptions can be knocked off course if tighter drug price regulation or more aggressive vertical integration by manufacturers and payers reduces McKesson’s role and margins.

Find out about the key risks to this McKesson narrative.

Another angle on McKesson’s valuation

That near fair value call at $980.40 contrasts sharply with our DCF model, which points to a future cash flow value of $1,481.84 and flags McKesson as trading at a 33.4% discount. When one model says slightly overvalued and another says meaningfully undervalued, which do you trust?

Look into how the SWS DCF model arrives at its fair value.

Next Steps

With mixed signals on value and plenty of debate around the story, it makes sense to look at the numbers yourself and move quickly to form your own view. A good place to start is the 3 key rewards and 1 important warning sign that sits behind this narrative.

Looking for more investment ideas?

If McKesson has sharpened your thinking, do not stop here. Your next strong move might be hiding in plain sight among other stocks that fit your style.

• Target potential mispricings by scanning 49 high quality undervalued stocks. See which companies currently line up with solid fundamentals at prices that might not fully reflect them yet.
• Build a steadier income stream by reviewing 13 dividend fortresses. Focus on businesses offering higher yields with an emphasis on durability.
• Sleep easier at night by checking 76 resilient stocks with low risk scores. This allows you to concentrate on companies with more resilient profiles instead of constant day to day drama.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com